We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further than most people outside healthcare recruiting realise.
What might be less obvious is how directly that shortage connects to the life sciences sector. The physician pipeline does not just supply hospital wards. It supplies research labs, clinical trial sites, academic health centres, and the institutions responsible for translating biomedical discovery into actual patient care. When that pipeline thins, the effects don’t stay contained to staffing dashboards.
The Numbers Behind the Shortage
The AAMC projects a physician shortfall of between 37,000 and 124,000 by 2036, spanning both primary and specialty care. That is a wide range, but even the conservative end represents a serious structural problem. What makes it worse is the age profile of the current workforce: roughly 20% of practicing physicians are 65 or older, and another 22% are between 55 and 64. A retirement wave is coming, and the training pipeline has not grown fast enough to absorb it.
From a placement standpoint, we feel this most acutely in specialties such as oncology, neurology, and infectious diseases. Searches in these areas regularly run three to six months for permanent roles. During that window, facilities operate short, rely on locum tenens coverage, or in the worst cases, scale back services. For a community hospital that is also running an active clinical trial, scaling back is not really an option.
What This Means for Clinical Research
Physician-scientists, the professionals who straddle clinical practice and biomedical research, account for roughly a third of NIH principal investigators. That cohort is aging alongside the rest of the physician workforce, and the path to replacing them is long and expensive. Medical training that combines clinical competency with research fluency takes time to build, and the economics of academic medicine increasingly push clinicians toward revenue-generating patient care rather than research.
At the trial site level, the impact is practical and immediate. Investigator turnover delays studies. Unfilled coordinator roles create recruitment backlogs. A site that loses its principal investigator mid-trial faces months of operational disruption while a replacement is found, credentialed, and brought up to speed. This is not an edge case. The Association of Clinical Research Professionals has tracked a pattern they call the ‘one and done’ PI, investigators who lead a single study and do not return. The clinical research workforce is churning in ways that compound the broader physician shortage problem.
Technology Cannot Outrun the People Problem
There is a lot of optimism in life sciences right now about decentralised trial models, AI-assisted diagnostics, and digital health platforms. That optimism is mostly warranted. But every one of those innovations still requires trained clinicians to implement, oversee, and validate it in real-world settings. You cannot decentralise a trial if the sites running it are understaffed. You cannot deploy a new diagnostic tool if the specialists qualified to interpret its outputs are not available.
This is where workforce planning and research strategy need to be thought about together rather than separately. The availability of qualified clinical personnel at trial sites is a direct variable in how quickly research moves. Sponsors and CROs increasingly understand this, but site-level institutions often still treat staffing as an operational concern rather than a scientific one.
What a More Flexible Model Looks Like
Locum tenens and flexible staffing arrangements have historically been associated with coverage gaps and rural facilities. That framing is outdated. Academic medical centres and research institutions are increasingly using temporary and contract clinical placements as a deliberate strategy to protect operational continuity, maintain trial activity during permanent hiring searches, and access specialised expertise for specific programme phases.
It is not a perfect solution to a structural problem. But it is a practical one. And the life sciences sector, which has grown very good at managing complexity in drug development, could benefit from applying that same rigour to the workforce question.
The pipeline of new therapies, diagnostics, and technologies coming out of life sciences research is genuinely impressive. What we need to make sure of is that the clinical infrastructure required to deliver on that promise, staffed by qualified, available physicians and investigators, is keeping pace with the science itself.
About the Author
Jody Talbert, Managing Partner and Co-Founder, Frontera Search Partners
Jody Talbert is Managing Partner and Co-Founder of Frontera Search Partners, a healthcare staffing firm working with over 700 facilities across the United States. With more than 20 years in healthcare, including direct patient care, Jody leads Frontera’s work placing physicians and advanced practice providers in hospitals, clinics, and government health systems.
